Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 13/20 | 0.66 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16099569 | 0.99 | WNT3A (0.65) | WNT3AMCHR1HDAC1HDAC8HDAC6 | |
| SCHEMBL16098823 | 0.94 | WNT3A (0.66) | WNT3AHDAC1HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL17511822 | 0.94 | WNT3A (0.65) | WNT3AHDAC1HDAC8HDAC6 | |
| SCHEMBL16098623 | 0.90 | WNT3A (0.80) | WNT3AKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL16099220 | 0.89 | WNT3A (0.62) | WNT3AMCHR1HDAC1HDAC8HDAC6 | |
| SCHEMBL17539214 | 0.87 | WNT3A (0.59) | WNT3A | |
| SCHEMBL16097404 | 0.84 | WNT3A (0.80) | WNT3AKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL16097692 | 0.84 | WNT3A (0.74) | WNT3A | |
| SCHEMBL16097733 | 0.84 | WNT3A (0.62) | WNT3AHDAC1HDAC8HDAC6 | |
| SCHEMBL16098310 | 0.81 | WNT3A (0.67) | WNT3AMCHR1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| WO-2014147182-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052898-A1 | NOVEL COMPOUNDS | AADAC, NAT1, CCNA1 | WNT3A 4230/4885MCHR1 4601/4885HDAC1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.